Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

21 Jan 2022

Abstract excerpt

Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T cells from exhausted status and revive immune response against cancer cells. Based on the immense success in clinical trials, ten α-PD-1 (nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab) and three α-PD-L1 antibodies (atezolizumab,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer, Stress, Anesthesia, and Immune Response
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35062949
DOI: 10.1186/s12943-021-01489-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsPMID 35062949Read ↗

PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.Semantic proximity Read ↗

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancerSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Research progress on the intrinsic non‑immune function of PD‑L1 in tumors (Review)Semantic proximity Read ↗

Regulatory mechanisms of PD-1/PD-L1 in cancersSemantic proximity Read ↗

PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applicationsSemantic proximity Read ↗

Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applicationsSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy.Semantic proximity Read ↗

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapySemantic proximity Read ↗

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.Semantic proximity Read ↗

Clinical implications of tumor-intrinsic mechanisms regulating PD-L1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.